Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001558370-25-003750
Filing Date
2025-03-27
Accepted
2025-03-27 07:30:28
Documents
74
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K avte-20241231x10k.htm   iXBRL 10-K 2158231
2 EX-23.1 avte-20241231xex23d1.htm EX-23.1 2263
3 EX-31.1 avte-20241231xex31d1.htm EX-31.1 10972
4 EX-31.2 avte-20241231xex31d2.htm EX-31.2 10917
5 EX-32.1 avte-20241231xex32d1.htm EX-32.1 5847
6 EX-32.2 avte-20241231xex32d2.htm EX-32.2 5958
  Complete submission text file 0001558370-25-003750.txt   8514867

Data Files

Seq Description Document Type Size
7 EX-101.SCH avte-20241231.xsd EX-101.SCH 39677
8 EX-101.CAL avte-20241231_cal.xml EX-101.CAL 66187
9 EX-101.DEF avte-20241231_def.xml EX-101.DEF 136757
10 EX-101.LAB avte-20241231_lab.xml EX-101.LAB 388498
11 EX-101.PRE avte-20241231_pre.xml EX-101.PRE 306139
77 EXTRACTED XBRL INSTANCE DOCUMENT avte-20241231x10k_htm.xml XML 1634456
Mailing Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451
Business Address 930 WINTER STREET SUITE M-500 WALTHAM MA 02451 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40544 | Film No.: 25775307
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)